SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Nimbus Therapeutics to Present Preclinical Rheumatoid Arthritis Data at ACR Convergence

Nimbus says selective SIK2 inhibitors reduced disease activity in a mouse model of rheumatoid arthritis. The company plans to present the preclinical data at ACR Convergence 2026.

Related stories